 CAMBRIDGE, Mass., June 25, 2021 GLOBE NEWSWIRE -- Trillium Therapeutics Inc. Trillium or the Company NASDAQTSX: TRIL, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, joins the broad-market Russell 2000 and 3000 Indices effective after the US market opens on June 28. 